



February 9, 2022

To whom it may concern,

Company: Japan Lifeline Co., Ltd.  
Representative: Keisuke Suzuki, President and CEO  
(Code: 7575 TSE 1st Section)  
Contact person: Kenji Yamada, Senior Vice President,  
Corporate Administration Headquarters  
(TEL. +81-3-6711-5200)

**Japan Lifeline Announces First Case in Japan of an Implantable Treatment Device  
for Obstructive Sleep Apnea**

Japan Lifeline Co., Ltd. (“Japan Lifeline”) is pleased to announce that the first implant case in Japan of the Inspire Upper Airway Stimulation (“the Inspire UAS”), an implantable treatment device for obstructive sleep apnea (OSA) syndrome manufactured by Inspire Medical Systems, Inc., has been completed on February 4<sup>th</sup>, 2022.

The Inspire UAS is a medical device that consists of a pulse generator for electrical stimulation, a sensor lead that detects patient breathing, and a stimulation lead that transmits electrical stimulation. The sensor lead detects the patient’s breathing cycle during sleep, and then the pulse generator delivers weak electrical stimulation to the hypoglossal nerve via the stimulation lead to open the airway, thereby treating OSA.

The first domestic case was performed at the Dokkyo Medical University Hospital with Associate Professor Itsuo Nakajima of the Department of Otorhinolaryngology, Head and Neck Surgery as the primary surgeon. Shinichi Haruna, Chairman, Professor of Otorhinolaryngology, Head and Neck Surgery at the Dokkyo Medical University, commented on the case that, "We are pleased to have successfully conducted the long-awaited first case of the Inspire UAS in Japan. This device will provide a new treatment option for patients who are unsuitable or intolerant of CPAP\*<sup>1</sup> therapy. It is already a widespread treatment method in Europe and the U.S., and with long-term clinical results, its safety and efficacy have been established. We would like to promote this latest sleep improvement treatment in Japan."

The Inspire UAS received CE Mark approval in 2010 and FDA approval in 2014, and already has an extensive clinical track record of more than 20,000 cases in Europe and the United States. On the other hand, the Inspire UAS is the first implantable device for OSA treatment in Japan, which requires training for physicians. Japan Lifeline intends to leverage its extensive experience in handling cardiac pacemakers and other implantable devices to promote the widespread use of the system by providing sufficient support to medical professionals working on the treatment of sleep disordered breathing.

**About Inspire Medical Systems, Inc.**

Inspire Medical Systems, Inc., based in Minneapolis, Minnesota, USA, was founded in 2007 as a spin-out from Medtronic. The company has developed a standard treatment for obstructive sleep apnea (OSA) and aims to improve the quality of life for all patients suffering from OSA. The company's one-and-only implantable device in the world, the Inspire UAS, received FDA approval in 2014 as the first FDA approved neurostimulation treatment device for OSA. As of today, the company has a track record of more than 20,000 implants worldwide. The company is listed on the New York Stock Exchange. (Securities code: INSP) For details, please refer to the website below. <https://www.inspiresleep.com/>